

- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)


Osteomark®
[Professional Products](#) [Brands](#)

- [Companies](#)
- [Professional Products](#)
- [Disease Areas](#)
- [Brands](#)
- [Acceava®](#)
- [BinaxNOW®](#)
- [Cholestech LDX®](#)
- [Clearview®](#)
- [Determine®](#)
- [DoubleCheckGold](#)
- [DoubleCheckGold Ultra](#)
- [Immunocomb®](#)
- [INRatio®](#)
- [Inverness Medical](#)
- [TestPack®](#)
- [Matritech®](#)
- [Osteomark®](#)
- [Panbio®](#)
- [SureStep](#)
- [Triage®](#)
- [Wampole](#)
- [Distributed Products](#)
- [Health Management](#)
- [Consumer](#)

Osteomark®

Osteomark® NTx urine and serum ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx), a specific biochemical indicator of bone resorption. Higher levels in serum or urine samples provide evidence of elevated bone resorption and thus of osteoporosis risk.

Osteomark® NTx assays are specific assays sensitive to subtle changes in levels of bone resorption.

Osteoporosis is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures. Osteoporosis affects both men and women, although postmenopausal women are at greater risk of developing the disease. Osteomark® Ntx ELISAs provide an accurate measurement of bone resorption, which helps in the diagnosis and monitoring of osteoporosis and in predicting accelerated decrease in bone mass in postmenopausal women. When used in conjunction with bone mineral density measurement, Osteomark® NTx gives a more complete picture of bone status than either technology alone.

Osteomark®